IGC Pharma (IGC) Cost of Revenue (2010 - 2025)
IGC Pharma (IGC) reported Cost of Revenue of $92000.0 for Q3 2025, down 57.01% year-over-year from $214000.0 in Q3 2024, and down 47.13% quarter-over-quarter from $174000.0 in Q2 2025.
IGC Pharma (IGC) Cost of Revenue (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has 16 years of Cost of Revenue data on file, last reported at $92000.0 in Q3 2025.
- Cost of Revenue for Q3 2025 came in at $92000.0, down 57.01% year-over-year; the trailing twelve-month figure through Sep 2025 was $595000.0 (up 14.86% YoY), and the FY2026 annual result was $262000.0, down 59.82% from the prior year.
- Cost of Revenue eased to $92000.0 in Q3 2025 per IGC's latest filing, from $174000.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $300000.0 in Q2 2023 and troughed at $18000.0 in Q3 2021.
- A 5-year average of $118789.5 and a median of $103000.0 in 2023 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2021 and 2023: Cost of Revenue plunged 90.52% in 2021, then surged 328.57% in 2023.
- A 5-year view of Cost of Revenue shows it stood at $80000.0 in 2021, then soared by 187.5% to $230000.0 in 2022, then tumbled by 69.13% to $71000.0 in 2023, then surged by 115.49% to $153000.0 in 2024, then slumped by 39.87% to $92000.0 in 2025.
- Business Quant data shows IGC's Cost of Revenue at $92000.0 in Q3 2025, $174000.0 in Q2 2025, and $176000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 2.05 Mn |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 92,000.00 |
| Sep 30, 2025 | 92,000.00 |
| Jun 30, 2025 | 174,000.00 |
| Jun 30, 2025 | 174,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Sep 30, 2024 | 214,000.00 |
| Sep 30, 2024 | 214,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Mar 31, 2024 | 124,000.00 |
| Mar 31, 2024 | 124,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Sep 30, 2023 | 117,000.00 |
| Sep 30, 2023 | 117,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 300,000.00 |